2024 EHA Congress MCL Highlights

CME

Independent Conference Highlights of the 2024 EHA Congress: Spotlight on Mantle Cell Lymphoma

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: August 23, 2024

Expiration: August 22, 2025

Activity

Progress
1 2
Course Completed

References

  1. Cheson BD, Sharman JP. Current approaches and novel new agents in the treatment of chronic lymphocytic leukemia. JCO Oncol Pract. 2024;[Epub ahead of print].
  2. Wang M, Mayer J, Belada D et al. Acalabrutinib plus bendamustine and rituximab in untreated mantle cell lymphoma: results from the phase 3, double-blind, placebo-controlled ECHO trial. Presented at: 2024 European Hematology Association Congress; June 13-16, 2024. Abstract LB3439.
  3. Kumar A, Soumerai J, Karmali R, et al. Preliminary safety and efficacy of BOVen (zanubrutinib, obinutuzumab, and venetoclax) for frontline therapy for older patients with mantle cell lymphoma. Presented at: 2024 European Hematology Association Congress; June 13-16, 2024. Abstract P1138.
  4. Lu J, Do B, Primeaux B. Evaluation of second-generation Bruton's tyrosine kinase inhibitors for the treatment of mantle cell lymphoma. J Oncol Pharm Pract. 2024;[Epub ahead of print].
  5. Le Gouill S, Morschhauser F, Chiron D, et al. Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial. Blood. 2021;137:877-887.
  6. Tam CS, Wang M, Simpson D, et al. Updated safety and efficacy data in the phase 1 trial of patients with mantle cell lymphoma (MCL) treated with Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (BGB-3111). Hematol Oncol. 2019;37:245-247.
  7. Jurczak W, Wang M, Trneny M. Efficacy and safety of ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) and TP53 mutations in the SYMPATICO study. Presented at: 2024 European Hematology Association meeting; June 13-16, 2024. Abstract P1128.
  8. Phillips T, Carlo-Stella C, Morschhauser F, et al. Glofitamab monotherapy in patients with heavily pretreated relapsed or refractory mantle cell lymphoma: updated analysis from a phase I/II study. Presented at: 2024 European Hematology Association Annual Congress; June 14, 2024. Abstract S231.
  9. Phillips TJ, Matasar M, Eyre TA, et al. GLOBRYTE: A phase 3, open-label, multicenter, randomized trial evaluating glofitamab monotherapy in patients with relapsed or refractory mantle cell lymphoma. Blood. 2023;142(Suppl 1):3052.
  10. Wang M, Munoz J, Goy A, et al. Three-year follow-up of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, including hig-risk subgroups, in the ZUMA-2 study. J Clin Oncol. 2023;41:555-567.
  11. Mant S, Naylor GU, Crosbie N, et al. A prospective analysis of newly diagnosed mantel cell lymphoma: predictors and survival of indolent disease. Presented at: 2024 European Hematology Association  Annual Congress; June 14, 2024. Abstract S230.
  12. Kumar A, Ying Z, Alperovich A, et al. Clinical presentation determines selection of patients for initial observation in mantle cell lymphoma. Haematologica. 2019;104:e163-e166
  13. Pahnke S, Abalo K, Ekberg S, et al. Clinical characteristics and outcomes of MCL patients aged 80 years and older. Abstract P1129. Presented at: 2024 European Hematology Association Annual Congress; June 14, 2024; Madrid, Spain. Abstract P1129.